Medicare scales back new drug pricing model
The Trump administration released the final version of a Medicare payment model intended to lower prices for drugs administered in doctors’ offices by aligning payments with prices in other countries. The source describes the finalized approach as scaled back but does not provide details on its scope, implementation schedule, or expected savings.
The Trump administration rolled out the final version of a new Medicare payment model aimed at lowering the prices of drugs administered in doctors’ offices.
The model is intended to align Medicare payments for those drugs with prices paid in countries overseas. The supplied report does not identify the countries used for comparison or specify which drugs, providers, or patients would be covered.
The source describes the final version as scaled back from the earlier proposal, but it does not explain which provisions were changed or removed. It also does not provide an implementation date, payment figures, projected savings, or details about how the model would operate.
THE QUESTIONS THIS EVENT LEAVES BEHIND
What provisions were removed or narrowed before the final model was released?
Which countries and pricing benchmarks will determine the overseas comparisons?
How could the model affect doctors’ offices that administer the covered drugs?
What evidence will show whether the model lowers Medicare spending without limiting access?
Who will oversee the model and decide whether it should be expanded or changed?
YOUR QUESTION
Does this story leave you with another question?
Send us the question the report did not answer. It may become the next question IAQ investigates.
GLOBAL CURIOSITY MAP · SEPTEMBER 2026